Programmed cell death protein 1/programmed death ligand-1 checkpoint blockade meets patient-derived organoids
Sun, L.; Yang, H.; Mao, Y.
Annals of Translational Medicine 7(Suppl. 8): S287
2019
ISSN/ISBN: 2305-5839
PMID: 32016006
DOI: 10.21037/atm.2019.11.76
Accession: 069779148
PDF emailed within 0-6 h: $19.90
Related References
Ness, N.; Andersen, S.; Khanehkenari, M.Rakaee.; Nordbakken, C.V.; Valkov, A.; Paulsen, E-Elise.; Nordby, Y.; Bremnes, R.M.; Donnem, T.; Busund, L-Tove.; Richardsen, E. 2017: The prognostic role of immune checkpoint markers programmed cell death protein 1 (PD-1) and programmed death ligand 1 (PD-L1) in a large, multicenter prostate cancer cohort Oncotarget 8(16): 26789-26801Li, M.-B.; Yang, Y.; Rafi, A.A.; Oschmann, M.; Grape, E.S.; Inge, A.K.; Córdova, A.; Bäckvall, J.-E. 2020: Silver-Triggered Activity of a Heterogeneous Palladium Catalyst in Oxidative Carbonylation Reactions Angewandte Chemie 59(26): 10391-10395
Tan, D.S.W. 2017: Changing the Natural History of Non-Small-Cell Lung Cancer Through Upfront Programmed Death Protein 1/Programmed Death-Ligand 1 Blockade Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 35(24): 2735-2736
Chen, J.; Chen, Y.; Feng, F.; Chen, C.; Zeng, H.; Wen, S.; Xu, X.; He, J.; Li, J. 2018: Programmed cell death protein-1/programmed death-ligand 1 blockade enhances the antitumor efficacy of adoptive cell therapy against non-small cell lung cancer Journal of Thoracic Disease 10(12): 6711-6721
Liu, X.; Cao, Y.; Li, R.; Gu, Y.; Chen, Y.; Qi, Y.; Lv, K.; Wang, J.; Yu, K.; Lin, C.; Liu, H.; Zhang, H.; He, H.; Chen, L.; Zhang, P.; Shen, Z.; Qin, J.; Sun, Y.; Li, H.; Huang, H.; Zhang, W.; Xu, J. 2020: Poor clinical outcomes of intratumoral dendritic cell-specific intercellular adhesion molecule 3-grabbing non-integrin-positive macrophages associated with immune evasion in gastric cancer European Journal of Cancer 128: 27-37
Gao, Y.; Li, S.; Xu, D.; Chen, S.; Cai, Y.; Jiang, W.; Zhang, X.; Sun, J.; Wang, K.; Chang, B.; Wang, F.; Hong, M. 2017: Prognostic value of programmed death-1, programmed death-ligand 1, programmed death-ligand 2 expression, and CD8(+) T cell density in primary tumors and metastatic lymph nodes from patients with stage T1-4N+M0 gastric adenocarcinoma Chinese Journal of Cancer 36(1): 61
Remon, J.; Chaput, N.; Planchard, D. 2016: Predictive biomarkers for programmed death-1/programmed death ligand immune checkpoint inhibitors in nonsmall cell lung cancer Current Opinion in Oncology 28(2): 122-129
Kunkle, C.; Rosado, F.G. 2018: The Role of the Programmed Death Receptor-1/Programmed Death Ligand-1: Immunologic Checkpoint in Human Papillomavirus-Associated Head and Neck Squamous Cell Carcinoma Archives of Pathology and Laboratory Medicine 142(6): 719-720
Zhang, Q.; Qi, Z.; Bo-Liu; Li, C-Sheng. 2018: Programmed Cell Death-1/Programmed Death-Ligand 1 Blockade Improves Survival of Animals with Sepsis: A Systematic Review and Meta-Analysis Biomed Research International 2018: 1969474
Zhang, N.; Tu, J.; Wang, X.; Chu, Q. 2019: Programmed cell death-1/programmed cell death ligand-1 checkpoint inhibitors: differences in mechanism of action ImmunoTherapy 11(5): 429-441
Villasboas, J.Caetano.; Ansell, S. 2016: Checkpoint Inhibition: Programmed Cell Death 1 and Programmed Cell Death 1 Ligand Inhibitors in Hodgkin Lymphoma Cancer Journal 22(1): 17-22
Hu-Lieskovan, S.; Ribas, A. 2017: New Combination Strategies Using Programmed Cell Death 1/Programmed Cell Death Ligand 1 Checkpoint Inhibitors as a Backbone Cancer Journal 23(1): 10-22
Arbour, K.C.; Mezquita, L.; Long, N.; Rizvi, H.; Auclin, E.; Ni, A.; Martínez-Bernal, G.; Ferrara, R.; Lai, W.Victoria.; Hendriks, L.E.L.; Sabari, J.K.; Caramella, C.; Plodkowski, A.J.; Halpenny, D.; Chaft, J.E.; Planchard, D.; Riely, G.J.; Besse, B.; Hellmann, M.D. 2018: Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non-Small-Cell Lung Cancer Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 36(28): 2872-2878
Tanaka, S.; Uchino, J. 2019: Erlotinib as standard adjuvant therapy for resectable EGFR mutation-positive non-small cell lung cancer Translational Lung Cancer Research 8(Suppl 4): S369-S372
Fu, H.; Du, B.; Chen, Z.; Li, Y. 2020: Radiolabeled Peptides for SPECT and PET Imaging in the Detection of Breast Cancer: Preclinical and Clinical Perspectives Current Medicinal Chemistry 27(41): 6987-7002